Loading, please wait...
Date: Jan 21, 2022 02:00 PM - 02:45 PM
Location: UIW Feik School of Pharmacy, 703 E. Hildebrand, San Antonio, TX, 78212
CE Hours
1.00
CE Units
0.100
Registration closes on Mar 04, 2022 11:55 PM
Activity Type
- Application
Target Audience(s)
- Pharmacists
Accreditation(s)
|
The University of the Incarnate Word Feik School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
|
Requirements for CE Credit
- The participant will only receive credit for programs after receiving a 70% on a post-test and an evaluation form is completed and submitted.
- The entire session must be attended to receive credit. No partial credit will be given.
- Certificates will not be mailed. Contact hours will be uploaded to NABP's CPE Monitor after successful completion of post-test and program evaluation.
- To receive credit, participant profiles must contain a valid NABP e-profile ID number and month/date of birth.
- All requirements to receive credit must be completed within six weeks of participation in the CPE program. Failure to complete requirements within the six-week window will result in no credit awarded to the participant.
Registration closes on Mar 04, 2022
at 11:55 PM
Registration closes on Mar 04, 2022
at 11:55 PM
Registration Closed
Registration Closed
Upon completion of this activity, pharmacists will be able to:
1. Discuss the current guideline recommendations of anticoagulation in patients with atrial fibrillation following valve replacement.
2. Analyze primary literature evaluating the use of direct oral anticoagulants (DOAC) in patients with atrial fibrillation and bioprosthetic valves.
3. Evaluate the risk versus benefit of using DOACs as compared to vitamin K antagonists (VKA) in patients with atrial fibrillation and bioprosthetic valves.
2. Analyze primary literature evaluating the use of direct oral anticoagulants (DOAC) in patients with atrial fibrillation and bioprosthetic valves.
3. Evaluate the risk versus benefit of using DOACs as compared to vitamin K antagonists (VKA) in patients with atrial fibrillation and bioprosthetic valves.
Speaker(s)/Author(s)
|
Harneal Diocee, PharmD |
Activity Number
0445-0000-22-001-L01-P
Date:
01/21/22
Time:
02:00 PM - 02:45 PM
CE Hours
1.00
Location
https://teams.microsoft.com/l/meetup-join/19%3amee
Registration Closed